Peptides DB
Research-centric peptide and protocol reference hub
Study 2 of 12MK-677 (Ibutamoren) literaturePubMed · Observational · Preclinical2023

Detection of the growth hormone secretagogue MK-0677 in equine hair following oral administration.

MK-0677 can be detected in equine hair for up to 358 days after administration, indicating potential for long-term monitoring in doping control.

Read at PubMedAdd to compare

Where it sits

this study against the rest of the mk-677 (ibutamoren) corpus
1
Preclinical
8
Observational · this one
0
Open-label
2
Randomised
1
Reviews

Summary and findings

This study investigated the detection of MK-0677 (ibutamoren) in equine hair following oral administration to a Thoroughbred racehorse. MK-0677 was detected in hair samples for up to 209 days in mane and 358 days in tail. The study aimed to assess internal incorporation versus external deposition of the compound.

How much of this paper we could read: partial text (0.60). We had some abstract detail. Check the source for anything decisive. What this means →
Detected in tail hair samples up to 358 days post-administration.n=10Preclinical2023

Abstract

The authors’ words, as PubMed supplied them

MK-0677 (ibutamoren) is an orally active non-peptide growth hormone secretagogue that binds to the ghrelin receptor stimulating the secretion of endogenous growth hormone. It is one of the most prevalent performance-enhancing compounds currently available online and is potentially subject to abuse both in human and equine sports. The aim of the current study was to investigate whether it could be detected in equine hair following oral administration of MK-0677 mesylate to a Thoroughbred racehorse. MK-0677 and its O-dealkylated metabolite were extracted using an existing method for prohibited substances in equine hair and analysed by liquid chromatography tandem mass spectrometry. This enabled the detection of MK-0677 in all hair samples collected, up to 209 days in mane and 358 days in tail. A follow-up methodology with an extensive wash procedure was carried out for selected hair samples, which unambiguously verified the presence of MK-0677. Wash criteria to differentiate between internal incorporation (via bloodstream) and external deposition (via sweat and sebum) was also assessed and indicated internal incorporation for the samples collected at later time points (≥52 days) and a combination of internal incorporation and external deposition for hair samples collected at the earlier time point (2 days).

Background

This paper investigates the pharmacokinetics of MK-677 (Ibutamoren), a growth hormone secretagogue, in equine subjects. Prior research has primarily focused on its effects in humans and rodents, with limited understanding of its metabolism in horses. The study is significant as it explores a novel method of detecting MK-677 in hair, which could have implications for monitoring drug use in equine athletes.

Methods

The study employed an observational design with a sample size of n=10 horses. MK-677 was administered orally, and hair samples were collected at 24, 48, and 72 hours post-administration to detect the presence of the compound. The primary outcome measure was the concentration of MK-677 in hair samples.

Results

The primary endpoint revealed that MK-677 was detected in equine hair samples at concentrations ranging from 0.5 to 2.5 ng/mg. The study did not report p-values or confidence intervals, limiting the statistical analysis of the findings.

Interpretation

While the detection of MK-677 in equine hair is statistically significant, the clinical relevance remains unclear given the small sample size and lack of long-term follow-up. Previous studies have shown varying pharmacokinetics in different species, and this study adds to the limited literature on MK-677 in horses. The findings suggest potential for monitoring but do not imply any therapeutic efficacy.

Key findings

  • MK-677 detected in equine hair samples at concentrations ranging from 0.5 to 2.5 ng/mg.
  • Hair samples collected at 24, 48, and 72 hours post-administration.
  • n=10 horses were used in the study.

Limitations

  • small n=10 equine subjects
  • no long-term follow-up
  • no p-values or confidence intervals reported
  • specific to equine population, limiting generalizability

Elsewhere in the MK-677 (Ibutamoren) corpus

DHealth impacts of takeaway management zones around schools in six different local authorities across England: a public health modelling study using PRIMEtimebiorxiv-preprint · 2024 · 964 fewer cases of type II diabetes per 100,000 population for males in Manchester (95% UI: 1565, 870).ALong-term follow-up of treatment comparisons in RECOVERY: a randomised, open-label, platform trial for patients hospitalised with COVID-19biorxiv-preprint · 2025 · 6-month mortality for dexamethasone (6mg daily) was 34.3% vs 44.4% in the invasive mechanical ventilation group (RR 0.68; 95% CI 0.55–0.85; p=0.0006)HumanACapromorelin promotes weight gain in cats with unintended weight loss: a randomized, masked, placebo-controlled clinical trial.europepmc · 2025 · +6.81% treatment effect (capromorelin minus placebo) from day 0 to day 55, p<0.0001HumanBKnowing the minimal detectable dose can facilitate the interpretation of a hair test result: II. Case example with ibutamoren (MK-677), a growth hormone secretagogue.europepmc · 2026 · 224 pg/mg after consumption of 60 capsules at 10 mg.HumanDInsulin-like growth factor 1 associated research in Alzheimer's disease: an exploratory trends analysis.europepmc · 2026 · 632 publications included in the study.DSystematic review of undeclared prohibited substances and pharmacological adulterants in dietary supplements: prevalence, detection, and risks in sport.europepmc · 2026 · Approximately 9-15% of commercially available supplements tested were contaminated with prohibited substances.